Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.

Cancer research - 1 Apr 2014

Deng Tao, Liu Jeff C, Chung Philip E D, Uehling David, Aman Ahmed, Joseph Babu, Ketela Troy, Jiang Zhe, Schachter Nathan F, Rottapel Robert, Egan Sean E, Al-Awar Rima, Moffat Jason, Zacksenhaus Eldad

Abstract excerpt

HER2(+) breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors. Many patients do not respond or relapse with aggressive metastatic disease. Therefore, there is an urgent need for new therapeutics that can target HER2(+) breast cancer and potentiate the effect of anti-HER2 inhibitors, in particular those that can target tumor-initiating cells (TIC). Here, we show that MMTV-Her2/Neu mammary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lapatinib

Share to Mice, SCID

Share to Quinazolines

Share to Receptor, ErbB-2

Share to RNA, Small Interfering

Share to Transcription Factor RelA

Source

Identifiers

PMID: 24487029
DOI: 10.1158/0008-5472.CAN-13-2138

Genes

TBK1
TANK
ULK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.PMID 24487029Read ↗

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsSemantic proximity Read ↗

IRAK2 contributes to triple-negative breast cancer growth via NF-κB, ERK and stress-related signaling pathwaysSemantic proximity Read ↗

Targeting of MARK2, but not other MARKs, suppresses TNBC progression by inhibition of the mutant p53-driven signaling pathway.Semantic proximity Read ↗

Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cellsSemantic proximity Read ↗

Polypharmacology-based kinome screen identifies new regulators of KSHV reactivationSemantic proximity Read ↗

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read ↗

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.Semantic proximity Read ↗

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like PhenotypeSemantic proximity Read ↗

Roles for the IKK-Related Kinases TBK1 and IKKε in CancerSemantic proximity Read ↗

ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.Semantic proximity Read ↗

TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.